Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes

Hong Wen Deng, Jian Li, Jin Long Li, Mark Johnson, Gordon Gong, K. Michael Davis, Robert R. Recker

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Our purpose is to assess whether genotypes of the vitamin D receptor (VDR) and estrogen receptor (ER) and their interaction influence changes in bone mass in postmenopausal Caucasian women with and without hormone replacement therapy (HRT). A population of 108 US Mid-West women who participated in a study of low-dose continuous estrogen/progestin was genotyped at the VDR BsmI site and the ER XbaI and PvuII sites. Adequate vitamin D and calcium nutritional intakes were assured in all the study subjects. For the 3.5-year duration of the study, we analyzed changes in bone mineral density (BMD) at the spine, femoral neck, distal radius, and the total body (total body bone mineral content, tbBMC). We adjusted for confounding factors, such as age and weight, in the analysis. We found that VDR and/or ER genotypes and/or their interaction generally had significant effects on the changes in the bone mass measurements in both the placebo and HRT groups. When a significant gene-by-gene interaction exists between VDR and ER genotypes, failure to account for them in analyses may yield nonsignificant results, even if significant genotypic effects exist. The amount of variation in changes in bone mass measurements explained by the total genotypic effects of the VDR and ER loci varies from ~ 1.0% (for the tbBMC changes in combined placebo and HRT groups) to ~ 18.7% (for the spine BMD changes in the HRT group). These results suggest that individual genotypes are important factors in determining changes in bone mass in the elderly with and without HRT and thus may need to be considered with respect to the treatment to preserve bone mass in elderly Caucasian women.

Original languageEnglish
Pages (from-to)576-585
Number of pages10
JournalHuman Genetics
Volume103
Issue number5
DOIs
StatePublished - 1998

Fingerprint

Calcitriol Receptors
Hormone Replacement Therapy
Estrogen Receptors
Bone Density
Genotype
Bone and Bones
Spine
Placebos
Femur Neck
Progestins
Vitamin D
Genes
Estrogens
Calcium
Weights and Measures
Population

All Science Journal Classification (ASJC) codes

  • Genetics(clinical)
  • Genetics

Cite this

Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes. / Deng, Hong Wen; Li, Jian; Li, Jin Long; Johnson, Mark; Gong, Gordon; Davis, K. Michael; Recker, Robert R.

In: Human Genetics, Vol. 103, No. 5, 1998, p. 576-585.

Research output: Contribution to journalArticle

Deng, Hong Wen ; Li, Jian ; Li, Jin Long ; Johnson, Mark ; Gong, Gordon ; Davis, K. Michael ; Recker, Robert R. / Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes. In: Human Genetics. 1998 ; Vol. 103, No. 5. pp. 576-585.
@article{7247bdee2ae54c85b0e2a8ae06038a9d,
title = "Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes",
abstract = "Our purpose is to assess whether genotypes of the vitamin D receptor (VDR) and estrogen receptor (ER) and their interaction influence changes in bone mass in postmenopausal Caucasian women with and without hormone replacement therapy (HRT). A population of 108 US Mid-West women who participated in a study of low-dose continuous estrogen/progestin was genotyped at the VDR BsmI site and the ER XbaI and PvuII sites. Adequate vitamin D and calcium nutritional intakes were assured in all the study subjects. For the 3.5-year duration of the study, we analyzed changes in bone mineral density (BMD) at the spine, femoral neck, distal radius, and the total body (total body bone mineral content, tbBMC). We adjusted for confounding factors, such as age and weight, in the analysis. We found that VDR and/or ER genotypes and/or their interaction generally had significant effects on the changes in the bone mass measurements in both the placebo and HRT groups. When a significant gene-by-gene interaction exists between VDR and ER genotypes, failure to account for them in analyses may yield nonsignificant results, even if significant genotypic effects exist. The amount of variation in changes in bone mass measurements explained by the total genotypic effects of the VDR and ER loci varies from ~ 1.0{\%} (for the tbBMC changes in combined placebo and HRT groups) to ~ 18.7{\%} (for the spine BMD changes in the HRT group). These results suggest that individual genotypes are important factors in determining changes in bone mass in the elderly with and without HRT and thus may need to be considered with respect to the treatment to preserve bone mass in elderly Caucasian women.",
author = "Deng, {Hong Wen} and Jian Li and Li, {Jin Long} and Mark Johnson and Gordon Gong and Davis, {K. Michael} and Recker, {Robert R.}",
year = "1998",
doi = "10.1007/s004390050872",
language = "English",
volume = "103",
pages = "576--585",
journal = "Human Genetics",
issn = "0340-6717",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes

AU - Deng, Hong Wen

AU - Li, Jian

AU - Li, Jin Long

AU - Johnson, Mark

AU - Gong, Gordon

AU - Davis, K. Michael

AU - Recker, Robert R.

PY - 1998

Y1 - 1998

N2 - Our purpose is to assess whether genotypes of the vitamin D receptor (VDR) and estrogen receptor (ER) and their interaction influence changes in bone mass in postmenopausal Caucasian women with and without hormone replacement therapy (HRT). A population of 108 US Mid-West women who participated in a study of low-dose continuous estrogen/progestin was genotyped at the VDR BsmI site and the ER XbaI and PvuII sites. Adequate vitamin D and calcium nutritional intakes were assured in all the study subjects. For the 3.5-year duration of the study, we analyzed changes in bone mineral density (BMD) at the spine, femoral neck, distal radius, and the total body (total body bone mineral content, tbBMC). We adjusted for confounding factors, such as age and weight, in the analysis. We found that VDR and/or ER genotypes and/or their interaction generally had significant effects on the changes in the bone mass measurements in both the placebo and HRT groups. When a significant gene-by-gene interaction exists between VDR and ER genotypes, failure to account for them in analyses may yield nonsignificant results, even if significant genotypic effects exist. The amount of variation in changes in bone mass measurements explained by the total genotypic effects of the VDR and ER loci varies from ~ 1.0% (for the tbBMC changes in combined placebo and HRT groups) to ~ 18.7% (for the spine BMD changes in the HRT group). These results suggest that individual genotypes are important factors in determining changes in bone mass in the elderly with and without HRT and thus may need to be considered with respect to the treatment to preserve bone mass in elderly Caucasian women.

AB - Our purpose is to assess whether genotypes of the vitamin D receptor (VDR) and estrogen receptor (ER) and their interaction influence changes in bone mass in postmenopausal Caucasian women with and without hormone replacement therapy (HRT). A population of 108 US Mid-West women who participated in a study of low-dose continuous estrogen/progestin was genotyped at the VDR BsmI site and the ER XbaI and PvuII sites. Adequate vitamin D and calcium nutritional intakes were assured in all the study subjects. For the 3.5-year duration of the study, we analyzed changes in bone mineral density (BMD) at the spine, femoral neck, distal radius, and the total body (total body bone mineral content, tbBMC). We adjusted for confounding factors, such as age and weight, in the analysis. We found that VDR and/or ER genotypes and/or their interaction generally had significant effects on the changes in the bone mass measurements in both the placebo and HRT groups. When a significant gene-by-gene interaction exists between VDR and ER genotypes, failure to account for them in analyses may yield nonsignificant results, even if significant genotypic effects exist. The amount of variation in changes in bone mass measurements explained by the total genotypic effects of the VDR and ER loci varies from ~ 1.0% (for the tbBMC changes in combined placebo and HRT groups) to ~ 18.7% (for the spine BMD changes in the HRT group). These results suggest that individual genotypes are important factors in determining changes in bone mass in the elderly with and without HRT and thus may need to be considered with respect to the treatment to preserve bone mass in elderly Caucasian women.

UR - http://www.scopus.com/inward/record.url?scp=0031736838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031736838&partnerID=8YFLogxK

U2 - 10.1007/s004390050872

DO - 10.1007/s004390050872

M3 - Article

VL - 103

SP - 576

EP - 585

JO - Human Genetics

JF - Human Genetics

SN - 0340-6717

IS - 5

ER -